Kairos Pharma, LTD.

Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company that advances therapeutics designed to overcome immune suppression and drug resistance in cancer patients. Its development pipeline includes antibodies, small molecules, and cell therapies targeting indications such as prostate cancer, lung cancer, breast cancer, and glioblastoma. The company's lead candidates include ENV 105, an antibody targeting CD105 to counter resistance in prostate and non-small cell lung cancers, and ENV 205, which targets extracellular mitochondrial DNA to address chemotherapy resistance. Its pipeline also features immunotherapeutic candidates such as KROS 101, an oral small-molecule GITR ligand modulator, and KROS 201, a dendritic-cell-activated T cell therapy for glioblastoma.

The company conducts clinical trials across multiple medical centers, including Cedars-Sinai Medical Center, the University of Utah, and City of Hope. Aside from off-site clinical trials performed at third-party facilities, its operations are conducted virtually. Kairos Pharma maintains its principal executive offices in Los Angeles, California.

Summary of the business section of Kairos Pharma's latest annual report, written by StockData.

“As of December 31, 2025, we had one full-time employee, our Chief Financial Officer, and three part-time employees (including our executive officers), each of whom is a part-time employee primarily engaged in research and development activities, and all hold M.D.”